The FDA on Tuesday launched a new programme aimed at making it easier for biopharma companies to begin Phase I trials of therapeutic candidates, formally opening the FDA Expedited IND Pilot QRI program to applications after months of public feedback and stakeholder engagement.
What the FDA Expedited IND Pilot QRI Program Actually Does
Dubbed the Expedited Investigational New Drug Pilot, the initiative invites drugmakers to partner with certain research groups to streamline new study starts. Acting FDA Commissioner Kyle Diamantas, along with Michael Davis and Karim Mikhail, the newly appointed permanent directors of the agency’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, penned an article outlining the rationale, calling it a “key priority of the Trump Administration to retain American leadership in biomedical advancements.”
The Timeline Gap Driving This Program
“A first-in-human clinical trial can take years to initiate in the United States versus just months in China and Australia,” the authors wrote, describing the country’s process as “unclear and lengthy” to navigate. The FDA argues these differences could affect not only U.S. scientific competitiveness but also how quickly American patients gain access to experimental therapies.
How Qualified Research Institutions Fit Into This FDA Expedited IND Pilot QRI Framework
To accelerate trial starts, FDA leaders proposed that drugmakers work with groups designated as qualified research institutions, or QRIs, such as academic medical centers or contract research organizations, to prepare high-quality IND applications. These QRIs will bring specialized and substantial scientific expertise to the IND application preparation process, according to Davis.
How Rolling Review Changes the Submission Process
The pilot will allow drug sponsors to submit individual IND components as they become ready, instead of waiting for the entire application to be complete. The FDA will begin reviewing nonclinical evidence, as well as chemistry, manufacturing and controls information and the product characterization package, on a rolling basis, helping the agency identify questions earlier so biopharmas can resolve issues in real time, reducing the risk that a first-in-human trial will need to be placed on hold.
The Scale and Timeline Behind This FDA Expedited IND Pilot QRI Launch
The FDA is targeting up to 10 sponsors paired with qualified research institutions for this initial round. The agency plans to review applications and select participants by Dec. 18, 2026, which would put selected pairs at the starting line around year-end.
Why This Remains Explicitly a Test, Not a New Pathway
This is a small pilot, and the FDA is explicit that it is a test rather than a new regulatory pathway. Nothing about the statutory or regulatory requirements for an IND has changed, and the agency has kept every formal decision-making authority right where it was; what’s being tested is whether earlier, more collaborative preparation between sponsors and QRIs produces cleaner INDs and fewer clinical holds.
How FDA Leaders Are Addressing Conflict-of-Interest Concerns Within This Pilot
Conflicts of interest came up in public comments on the proposal. Mikhail said the FDA is not delegating its authority to anyone and that review teams will continue to conduct standard IND reviews during the pilot. The pilot’s webpage includes specific conflict-of-interest requirements addressing how QRIs and sponsors must structure their partnerships.
Addressing Concerns About Added Bureaucracy
On the question of whether adding a QRI could introduce bureaucracy rather than remove it, Davis said the expectation is that the sponsor and institution will have already worked through internal discussion and refinement of the IND before it reaches the FDA, describing the pilot as built to reduce “unnecessary delays at every stage of early development.”
How This FDA Expedited IND Pilot QRI Program Fits Within Operation TrialBlazer
Diamantas said the FDA will continue implementing Operation TrialBlazer to modernize regulatory processes and strengthen U.S. competitiveness while maintaining patient safety. Sponsors and participating institutions will also be encouraged to coordinate activities such as Institutional Review Board review and clinical trial site activation alongside IND development and FDA review, addressing delays that occur outside the formal regulatory review process itself.
Why Coordinating IRB Review Matters for Overall Trial Timelines
By explicitly encouraging sponsors to coordinate IRB review and site activation in parallel with IND development, rather than treating these as sequential steps, the pilot targets a broader set of bottlenecks beyond FDA review alone, since IRB approval and site activation delays have historically added significant time to the overall path from drug identification to first-in-human dosing.
What This FDA Expedited IND Pilot QRI Program Means Going Forward
With applications open and a Dec. 18 selection deadline set, biopharma companies and research institutions interested in participating have a defined but compressed window to form partnerships and prepare applications for this initial cohort of up to 10 pairs. Given that Davis and Mikhail were only named permanent CDER and CBER directors after serving in acting capacities as recently as early September, this pilot’s launch also reflects a broader period of FDA leadership stabilization occurring simultaneously with the agency’s push to accelerate early clinical development timelines.
What to Watch Going Forward
As the FDA reviews applications ahead of its December selection deadline, industry observers will likely watch which academic medical centers, healthcare networks, and contract research organizations emerge as active QRI partners, and whether the rolling review process measurably reduces clinical hold rates among the pilot’s initial participants. Given the FDA’s explicit framing of this as a test of whether earlier, more collaborative preparation produces better outcomes, this FDA Expedited IND Pilot QRI program may inform whether the agency eventually expands rolling review and institutional partnership models beyond this initial small-scale pilot into a more permanent feature of the IND process.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed
